Use the keywords feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#1
REVIEW
Delaram Safarpour, Natividad Stover, David R Shprecher, Ali G Hamedani, Ronald F Pfeiffer, Henry P Parkman, Eamonn Mm Quigley, Leslie J Cloud
BACKGROUND: Gastrointestinal (GI) dysfunction is a common non-motor feature of Parkinson disease (PD). GI symptoms may start years before the onset of motor symptoms and impair quality of life. Robust clinical trial data is lacking to guide screening, diagnosis and treatment of GI dysfunction in PD. OBJECTIVE: To develop consensus statements on screening, diagnosis, and treatment of GI dysfunction in PD. METHODS: The application of a modified Delphi panel allowed for the synthesis of expert opinions into clinical statements...
May 3, 2024: Parkinsonism & related Disorders
#2
REVIEW
Lynne V McFarland, Gail Hecht, Mary E Sanders, Debra A Goff, Ellie J C Goldstein, Colin Hill, Stuart Johnson, Maryam R Kashi, Ravina Kullar, Maria L Marco, Daniel J Merenstein, Mathieu Millette, Geoffrey A Preidis, Eamonn M M Quigley, Gregor Reid, Seppo Salminen, Jason C Sniffen, Harry Sokol, Hania Szajewska, Daniel J Tancredi, Kristin Woolard
IMPORTANCE: Systematic reviews and meta-analyses often report conflicting results when assessing evidence for probiotic efficacy, partially because of the lack of understanding of the unique features of probiotic trials. As a consequence, clinical decisions on the use of probiotics have been confusing. OBJECTIVE: To provide recommendations to improve the quality and consistency of systematic reviews with meta-analyses on probiotics, so evidence-based clinical decisions can be made with more clarity...
December 1, 2023: JAMA Network Open
#3
JOURNAL ARTICLE
Manuel A Garza, Braden Thomas, Adam Saleh, Lara Nabbout, Eamonn M M Quigley, Neha Mathur
BACKGROUND Clostridioides difficile (C. difficile) is a bacterium that is well known for causing serious diarrheal infections and can even lead to colon cancer if left untreated. Disruption of the normal healthy bacteria in the colon can lead to development of C. difficile colitis. Risk factors for C. difficile infections (CDI) include recent antibiotic exposure, hospital or nursing home stays, inflammatory bowel disease (IBD), or impaired immunity. There is an increasing incidence of community-associated CDI (CA-CDI) in individuals without the common risk factors, which has implicated natural reservoirs, zoonoses, originating from animals such as domestic cats and dogs, livestock, shellfish, and wild animals...
October 27, 2023: American Journal of Case Reports
#4
JOURNAL ARTICLE
Eamonn M M Quigley
Constipation is one of the most common gastrointestinal features of Parkinson's disease (PD), occurring in over 50% of all PD patients during the course of their disease. Furthermore, constipation is now recognized as an important, prodromal symptom and may predate the onset of the classical motor symptoms by decades. Thereafter, the prevalence and severity of constipation in PD tend to parallel the course of both motor and nonmotor phenomena such as cognitive decline and depression. Difficult defecation (obstructed defecation, dyssynergia) is the primary pathophysiology underlying constipation and likely reflects involvement by the PD process of one or more of the many skeletal muscle groups that are involved in effecting defecation...
August 2023: Seminars in Neurology
#5
JOURNAL ARTICLE
Vivek C Goodoory, Mais Khasawneh, Christopher J Black, Eamonn M M Quigley, Paul Moayyedi, Alexander C Ford
BACKGROUND & AIMS: Some probiotics may be beneficial in irritable bowel syndrome (IBS), but differences in species and strains used, as well as endpoints reported, have hampered attempts to make specific recommendations as to which should be preferred. We updated our previous meta-analysis examining this issue. METHODS: MEDLINE, EMBASE, and the Cochrane Controlled Trials Register were searched (up to March 2023). Randomized controlled trials (RCTs) recruiting adults with IBS, comparing probiotics with placebo were eligible...
November 2023: Gastroenterology
#6
REVIEW
Daniel Martin Simadibrata, Elvira Lesmana, Jeffri Gunawan, Eamonn Martin Quigley, Marcellus Simadibrata
BACKGROUND AND AIMS: Given the scale and persistence of COVID-19, significant attention has been given to understanding the relationship between human gut microbiota and COVID-19. This systematic review aims to comprehensively assess the gut microbiota composition in COVID-19 and recovered COVID-19 patients in comparison to healthy controls (HCs). METHODS: Peer-reviewed articles and preprints published up to September 1, 2022, were searched in Ovid MEDLINE, Ovid EMBASE, and SCOPUS...
June 2, 2023: Journal of Digestive Diseases
#7
JOURNAL ARTICLE
Ami D Sperber, Serhat Bor, Xuicai Fang, Shrikant I Bangdiwala, Douglas A Drossman, Uday C Ghoshal, Magnus Simren, Jan Tack, William E Whitehead, Dan L Dumitrascu, Shin Fukudo, John Kellow, Edith Okeke, Eamonn M M Quigley, Max Schmulson, Peter Whorwell, Timothy Archampong, Payman Adibi, Viola Andresen, Marc A Benninga, Bruno Bonaz, Luis Bustos Fernandez, Suck Chei Choi, Enrico S Corazziari, Carlos Francisconi, Albis Hani, Leonid Lazebnik, Yeong Yeh Lee, Agata Mulak, M Masudur Rahman, Javier Santos, Mashiko Setshedi, Ari Fahrial Syam, Stephen Vanner, Reuben K Wong, Aurelio Lopez-Colombo, Valeria Costa, Ram Dickman, Motoyori Kanazawa, Ammar Hassanzadeh Keshteli, Rutaba Khatun, Iradj Maleki, Pierre Poitras, Nitesh Pratap, Oksana Stefanyuk, Sandie Thomson, Murat Buyruk, Nalan Unal, Dan Huang, Jun Song, Johann P Hreinsson, Olafur S Palsson
BACKGROUND AND AIMS: The Rome Foundation Global Epidemiology Study (RFGES) assessed the prevalence, burden, and associated factors of Disorders of Gut-Brain Interaction (DGBI) in 33 countries around the world. Achieving worldwide sampling necessitated use of two different surveying methods: In-person household interviews (9 countries) and Internet surveys (26 countries). Two countries, China and Turkey, were surveyed with both methods. This paper examines the differences in the survey results with the two methods, as well as likely reasons for those differences...
April 5, 2023: Neurogastroenterology and Motility: the Official Journal of the European Gastrointestinal Motility Society
#8
REVIEW
Adam Saleh, Shyon Parsa, Manuel Garza, Eamonn M M Quigley, Bincy P Abraham
BACKGROUND: Considerable research supports an important role for the microbiome and/or microbiome-host immune system interactions in the pathogenesis of inflammatory bowel disease (IBD). Consequently, microbiota-modulating interventions, such as fecal microbiota transplantation (FMT), have attracted interest in the management of IBD, including ulcerative colitis (UC). SUMMARY: While the clinical response to FMT in UC has varied between different studies, results to date may offer guidance towards optimal use of FMT...
March 1, 2023: Digestive Diseases
#9
RANDOMIZED CONTROLLED TRIAL
Satish S C Rao, Eamonn M M Quigley, William D Chey, Amol Sharma, Anthony J Lembo
BACKGROUND & AIMS: Despite therapeutic advances, effective treatments for chronic constipation remain an unmet need. The vibrating capsule is a nonpharmacologic, orally ingested, programmable capsule that vibrates intraluminally to induce bowel movements. We aimed to determine the efficacy and safety of the vibrating capsule in patients with chronic constipation. METHODS: We conducted a phase 3, double-blind, placebo-controlled trial of patients with chronic constipation, who were randomized to receive either a vibrating or placebo capsule, once daily, 5 days a week for 8 weeks...
June 2023: Gastroenterology
#10
REVIEW
Daniel So, Eamonn M M Quigley, Kevin Whelan
PURPOSE OF REVIEW: The gastrointestinal (GI) microbiome has been implicated in the pathogenesis of inflammatory bowel disease (IBD) and has been linked with irritable bowel syndrome (IBS). The aim of this article is to critically review the emerging evidence for the mechanisms and effectiveness of probiotics in the management of these conditions. RECENT FINDINGS: The GI microbiome is strongly influenced by ageing, diet and disease. Probiotics may confer health effects to the host by modulating the metabolic activities of the microbiome to propagate anti-inflammatory effects and reinforce the intestinal barrier, and are considered to be safe to use...
March 1, 2023: Current Opinion in Gastroenterology
#11
EDITORIAL
Eamonn M M Quigley
No abstract text is available yet for this article.
April 2023: Gastroenterology
#12
JOURNAL ARTICLE
Pragnesh Patel, Malcolm Irani, Edward A Graviss, Duc T Nguyen, Eamonn M M Quigley, David W Victor
BACKGROUND: Patients with cirrhosis have a high risk for morbidity and mortality in relation to abdominal surgery. Despite improvements in surgical techniques and intensive care, major abdominal surgery still remains a challenge. Major factors determining short- and long-term survival and perioperative complications in this patient population include severity of liver dysfunction, degree of portal hypertension (PHTN), and the presence of related complications such as ascites. Elective transjugular intrahepatic portosystemic shunt (TIPS) placement prior to surgery has been reported to improve perioperative outcomes, but available data is limited to case reports and small case series...
2023: Translational Gastroenterology and Hepatology
#13
EDITORIAL
Eamonn M M Quigley, Alex Stevenson, Ian Jeffery, Jacob Masters
No abstract text is available yet for this article.
February 2023: Alimentary Pharmacology & Therapeutics
#14
JOURNAL ARTICLE
Ayushi Shah, Zunirah Ahmed, Fadl Zeineddine, Eamonn M M Quigley
BACKGROUND: Coronavirus disease 2019 (COVID-19) can lead to ventilator-dependent chronic respiratory failure and a need for tube feeding. Percutaneous endoscopic gastrostomy (PEG) placement provides more sustainable longer-term enteral access with fewer side effects compared to the long-term nasogastric tube placement. Bleeding is a recognized complication of PEG placement, and many COVID-19 patients are on antiplatelets/anticoagulants, yet minimal data exist on the safety of PEG tube placement in this context...
October 2022: Gastroenterology Research
#15
RANDOMIZED CONTROLLED TRIAL
Eamonn M M Quigley, Louise Markinson, Alex Stevenson, F Peter Treasure, Brian E Lacy
BACKGROUND: MRx1234 is a live biotherapeutic product that contains a strain of Blautia hydrogenotrophica. It is in development for the treatment of irritable bowel syndrome (IBS). AIMS: To assess the efficacy and safety of MRx1234 in patients with IBS with predominant constipation (IBS-C) or diarrhoea (IBS-D) METHODS: We conducted a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Patients aged 18-70 years in two parallel cohorts (IBS-C; IBS-D) were randomised (1:1) to MRx1234 or placebo for 8 weeks...
January 2023: Alimentary Pharmacology & Therapeutics
#16
EDITORIAL
Eamonn M M Quigley
No abstract text is available yet for this article.
November 2022: Alimentary Pharmacology & Therapeutics
#17
JOURNAL ARTICLE
Lissa Franco, Michelle Jones-Pauley, Omar Tamimi, Leila Neshatian, Duc Nguyen, Edward Graviss, Eamonn Mm Quigley, David Victor
GOALS: Determine factors associated with Irritable bowel syndrome (IBS) in nonalcoholic fatty liver disease (NAFLD) patients. BACKGROUND: IBS affects 10% to 15% of the adult population worldwide and is linked to anxiety and depression. The impact of IBS-type symptoms in NAFLD patients is not well described. STUDY: A cross-sectional study of patients in the hepatology clinic at Houston Methodist Hospital was performed based on a respondent postal survey...
October 10, 2022: Journal of Clinical Gastroenterology
#18
JOURNAL ARTICLE
David Groeger, Eileen F Murphy, Hern Tze Tina Tan, Ida Søgaard Larsen, Ian O'Neill, Eamonn M M Quigley
BACKGROUND: Stress is an exacerbator of irritable bowel syndrome (IBS) symptoms, and anxiety and depression are co-morbidities. Bifidobacterium longum strains 1714® and 35642® attenuate stress responses in healthy people and reduce symptoms in IBS, respectively. Here, we explore relationships between the psychological and visceral effects of the two strains (COMBO) in IBS subjects and biomarkers of stress and inflammation. METHODS: We recruited 40 patients with IBS (Rome III) and mild to moderate anxiety (HADS-A) and/or depression (HADS-D) and 57 asymptomatic female controls with low or moderate stress...
January 2023: Neurogastroenterology and Motility: the Official Journal of the European Gastrointestinal Motility Society
#19
JOURNAL ARTICLE
Peter Flood, Aine Fanning, Jerzy A Woznicki, Tadhg Crowley, Andrea Christopher, Alessandra Vaccaro, Aileen Houston, Sheila McSweeney, Sarah Ross, Aileen Hogan, Elizabeth Brint, Agnieszka Skowyra, Milan Bustamante, Monica Ambrose, Gerard Moloney, John MacSharry, Marie-Louise Hammarström, Margot Hurley, Christine Fitzgibbons, Eamonn M M Quigley, Fergus Shanahan, Syed A Zulquernain, Jane McCarthy, G Steven Dodson, Karim Dabbagh, Bradford L McRae, Silvia Melgar, Ken Nally
DNA sensor pathways can initiate inflammasome, cell death, and type I interferon (IFN) signaling in immune-mediated inflammatory diseases (IMIDs), including type I interferonopathies. We investigated the involvement of these pathways in the pathogenesis of ulcerative colitis (UC) by analyzing the expression of DNA sensor, inflammasome, and type I IFN biomarker genes in colonic mucosal biopsy tissue from control ( n = 31), inactive UC ( n = 31), active UC ( n = 33), and a UC single-cell RNA-Seq dataset. The effects of type I IFN (IFN-β), IFN-γ, and TNF-α on gene expression, cytokine production, and cell death were investigated in human colonic organoids...
November 1, 2022: American Journal of Physiology. Gastrointestinal and Liver Physiology
#20
JOURNAL ARTICLE
Nikola Fritz, Sabrina Berens, Yuanjun Dong, Cristina Martínez, Stefanie Schmitteckert, Lesley A Houghton, Miriam Goebel-Stengel, Verena Wahl, Maria Kabisch, Dorothea Götze, Mauro D'Amato, Tenghao Zheng, Ralph Röth, Hubert Mönnikes, Jonas Tesarz, Felicitas Engel, Annika Gauss, Martin Raithel, Viola Andresen, Jutta Keller, Thomas Frieling, Christian Pehl, Christoph Stein-Thöringer, Gerard Clarke, Paul J Kennedy, John F Cryan, Timothy G Dinan, Eamonn M M Quigley, Robin Spiller, Caroll Beltrán, Ana María Madrid, Verónica Torres, Emeran A Mayer, Gregory Sayuk, Maria Gazouli, George Karamanolis, Mariona Bustamante, Xavier Estivil, Raquel Rabionet, Per Hoffmann, Markus M Nöthen, Stefanie Heilmann-Heimbach, Börge Schmidt, André Franke, Wolfgang Lieb, Wolfgang Herzog, Guy Boeckxstaens, Mira M Wouters, Magnus Simrén, Gudrun A Rappold, Maria Vicario, Javier Santos, Rainer Schaefert, Justo Lorenzo-Bermejo, Beate Niesler
Irritable bowel syndrome (IBS) is a gut-brain disorder of multifactorial origin. Evidence of disturbed serotonergic function in IBS accumulated for the 5-HT3 receptor family. 5-HT3 Rs are encoded by HTR3 genes and control GI function, and peristalsis and secretion, in particular. Moreover, 5-HT3 R antagonists are beneficial in the treatment of diarrhea predominant IBS (IBS-D). We previously reported on functionally relevant SNPs in HTR3A c.-42C > T (rs1062613), HTR3C p.N163K (rs6766410), and HTR3E c...
September 19, 2022: Journal of Molecular Medicine: Official Organ of the "Gesellschaft Deutscher Naturforscher und Ärzte"
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
